Sonoma Pharmaceuticals, Inc. SNOA
Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) is a dermatology medical device company.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| HOCl wound and dermatology products (22 FDA 510(k) clearances) | Wound care, itch/pain relief, scar management | — | NA_NON_THERAPEUTIC |
Recent results and decisions
- Oct 6, 2026n/a Sonoma Pharmaceuticals adopts a Section 382 rights agreement to preserve net operating loss carryforwards and other tax benefits.
Our board of directors adopted the Rights Agreement to protect shareholder value by guarding against a potential limitation on our ability to use our net operating loss carryforwards, or NOLs, and other tax benefits, which may be used to reduce potential future income tax obligations.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other dermatology companies
- SkinHealth Systems Inc. SKIN
- Spectral AI, Inc. MDAI
- SANUWAVE Health, Inc. SNWV
- Nexgel, Inc. NXGL
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.